Evidence map›Paper›PMID 30291223›Full record

ArticleBlood cancer journal2018

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q).

Mikkael A Sekeres, Arlene S Swern, Aristoteles Giagounidis, Alan F List, Dominik Selleslag, Moshe Mittelman, Brigitte Schlegelberger, Gudrun Göhring, Jack Shiansong Li, Mary M Sugrue and 1 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Lowering the boom on lower-risk myelodysplastic syndromes.Hematology. American Society of Hematology. Education Program · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 5 countries.

Mikkael A SekeresCleveland Clinic, Cleveland, OH, USA. sekerem@ccf.org.
Arlene S SwernCelgene Corporation, Summit, NJ, USA.
Aristoteles GiagounidisMarien Hospital Düsseldorf, Düsseldorf, Germany.
Alan F ListMoffitt Cancer Center and Research Institute, Tampa, FL, USA.
Dominik SelleslagAZ Sint-Jan Brugge-Oostende, Bruges, Belgium.
Moshe MittelmanTel Aviv Sourasky Medical Center, Sackler Medical School, Tel Aviv University, Tel Aviv, Israel.
Brigitte SchlegelbergerInstitute of Human Genetics, Hannover Medical School, Hannover, Germany.
Gudrun GöhringInstitute of Human Genetics, Hannover Medical School, Hannover, Germany.
Jack Shiansong LiCelgene Corporation, Summit, NJ, USA.
Mary M SugrueFormerly Celgene Corporation, Summit, NJ, USA.
Pierre FenauxService d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France.
Medizinische Hochschule Hannover · DEAZ Sint-Jan · BECleveland Clinic · USHôpital Saint-Louis · FRMarien Hospital Düsseldorf · DEMoffitt Cancer Center · USTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Chromosome DeletionChromosomes, Human, Pair 5Antineoplastic AgentsFemaleHumansLenalidomideMaleMyelodysplastic SyndromesPrognosisTreatment OutcomeAntineoplastic AgentsLenalidomide

Identifiers

PMID30291223
PMCPMC6173782
OpenAlexW2889975345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.